BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24516696)

  • 1. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67.
    Shin IY; Sung NY; Lee YS; Kwon TS; Si Y; Lee YS; Oh ST; Lee IK
    Gut Liver; 2014 Jan; 8(1):13-23. PubMed ID: 24516696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
    Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
    J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein CD44 expression in colorectal neoplasms. An immuno-histochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices.
    Ioachim E; Goussia A; Agnantis NJ
    Virchows Arch; 1999 Jan; 434(1):45-50. PubMed ID: 10071234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
    Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
    Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
    Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
    Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoexpression of TS, p53, COX2, EGFR, MSH6 and MLH1 biomarkers and its correlation with degree of differentiation, tumor staging and prognostic factors in colorectal adenocarcinoma: a retrospective longitudinal study.
    Batista WR; Santos G; Vital FMR; Matos D
    Sao Paulo Med J; 2019 May; 137(1):33-38. PubMed ID: 31116268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
    Reinartz JJ; George E; Lindgren BR; Niehans GA
    Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-associated biomarker profiles of human breast cancer.
    Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
    Streckfus C; Bigler L; Tucci M; Thigpen JT
    Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.
    Hilbe W; Dirnhofer S; Oberwasserlechner F; Eisterer W; Ammann K; Schmid T; Hilbe G; Thaler J; Wöll E
    J Clin Pathol; 2003 Oct; 56(10):736-41. PubMed ID: 14514775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
    Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
    Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.